Participated · Series A · Jun 2022

Tyson 2.0 is a cannabis company founded by Chad Bronstein and Mike Tyson that produces and sells cannabis products across North America. The company reports sales in more than 20 U.S. states and Canada and has sold over 4,000 pounds of cannabis flower across North America. It closed a $9M Series A to support growth and strategic initiatives. Tyson 2.0 intends to use the funds to acquire more celebrity intellectual property, scale marketing efforts, accelerate distribution, and further develop its house-of-brands strategy. The company also announced the appointment of Nicole Cosby as Chief Legal and Licensing Officer; Cosby previously served as Chief Data and Compliance Officer of Fyllo Group and Senior Vice President of Standards at Publicis Group. The business positions itself as a premier, celebrity-fronted cannabis brand building out distribution and brand licensing.

Participated · Seed · Jun 2022

Wonder Sciences launched Wondermed, an at‑home ketamine‑assisted treatment that pairs low‑dose, self‑administered ketamine lozenges with a structured telehealth protocol integrating psychiatry and psychology. Patients complete an eligibility survey and clinician telehealth visit, then follow a personalized weekly session plan supported by remote check‑ins, soundscapes, journaling prompts and integration resources. Wondermed charges an introductory rate of $249 per month, which includes four lozenges for self‑led sessions, clinician support, and a personalized dashboard. The company reports that 92 percent of patients experience a decrease in anxiety following their first session. Wonder Sciences is accepting patients in California, New York, Florida and Texas, plans near‑term expansion into Illinois, Arizona and Connecticut, and aims to be available in 19 states by year‑end. The company is also developing a database of partner mental health professionals to provide recommendations to patients.

Participated · Seed · Dec 2021

Maya Health (Maya PBC) operates a real-world data platform and product suite that includes a Companion App for individuals, a Measurement Based Care Platform for providers, and a Real World Data Platform for researchers. The company positions itself to bridge psychedelic research and real-world practice by enabling collaboration among providers, participants, researchers, and regulators. It plans to bring its platform to market in 2022 and to expand personnel, develop its technologies, add business integrations for practitioners, and integrate with blockchain initiatives to enhance security, privacy, and transparency. Financially, Maya announced $4.3 million in its first investment rounds, consisting of an $800,000 angel round and a $3.5 million seed round. The platform is intended to accelerate pre-clinical research, enhance safety, optimize outcomes, and help reduce the cost of psychedelic care. Maya frames its mission around scaling psychedelic healthcare safely and effectively as a public benefit corporation based in Denver.

Participated · Equity · Mar 2021

Wesana Health focuses on developing psychedelic-assisted and naturally sourced treatments, including psilocybin-based medicine, to address neurological and psychological harms from traumatic brain injury. The company emphasizes evidence-based formulations and protocols developed through clinical research and academic partnerships. Proceeds from its recent financing will primarily fund preclinical and clinical development of its therapies and enable expansion of its senior leadership team. Wesana positioned the financing ahead of a planned go-public transaction via a reverse takeover. The company highlights patient empowerment and advancing alternative treatments for TBI as core mission priorities. No operating metrics (revenue or user figures) were disclosed in the announcement. Wesana Health is an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness. The company champions development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols to help patients overcome neurological, psychological and mental health ailments caused by trauma. The company announced the close of a $4 million convertible note financing round led by The Conscious Fund and Ambria Capital. Wesana positions itself around evidence-based approaches and academic collaborations as it advances its therapeutic programs. The financing reflects a capital event reported by the company to support its ongoing development activities.